FDC Ltd

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s Mojo Grade was downgraded from Hold to Sell on 17 August 2026, reflecting deteriorating technical and price action metrics amid broader market challenges.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained weakness in the near to medium term.

FDC Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 September 2026, providing investors with the latest insights into the company’s performance and outlook.

FDC Ltd is rated Sell by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Aug 2026. The downgrade reflects a combination of deteriorating technical indicators, subdued long-term financial growth, and waning institutional interest, despite recent quarterly earnings improvements.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical parameters, signalling a transition from a sideways trend to a mildly bearish outlook. This change is underscored by deteriorating momentum indicators and mixed signals from key technical tools, prompting a downgrade in its Mojo Grade from Hold to Sell as of 17 Aug 2026.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators present a mixed picture, with bearish signals dominating monthly charts while daily moving averages suggest mild bullishness. This article analyses the evolving price momentum, key technical indicators, and the implications for investors amid a challenging market backdrop.

FDC Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 August 2026, providing investors with the latest insights into the company’s performance and outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, reflects evolving market perceptions and presents a nuanced picture for investors assessing price attractiveness against sector peers and historical benchmarks.

FDC Ltd., a fully integrated research-oriented pharmaceutical company specialising in formulations and active pharmaceutical ingredients, reported a robust 28.13% quarter-on-quarter surge in net profit to ₹132.49 crores for Q1 FY27, up from ₹103.40 crores in Q4 FY26. On a year-on-year basis, the company posted a 9.17% increase from ₹121.36 crores in Q1 FY26. Despite the impressive profit growth, the stock tumbled 3.85% to ₹387.50 on August 05, 2026, reflecting investor concerns over historical margin inconsistency and persistent underperformance against benchmark indices.

FDC Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This transition, driven by changes in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a detailed analysis of its price attractiveness relative to historical levels and peer companies within the sector.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and a return to positive financial performance. The MarketsMOJO Mojo Score now stands at 58.0, signalling cautious optimism amid mixed long-term fundamentals and valuation concerns.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a slight dip in the latest session, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, suggesting cautious optimism for investors analysing its near-term prospects.